SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

CORRESP Filing

Dermata Therapeutics, Inc.
Date: April 21, 2025 · CIK: 0001853816 · Accession: 0001641172-25-005582

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-286547

Date
April 21, 2025
Author
By
Form
CORRESP
Company
Dermata Therapeutics, Inc.

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance File No. 333-286547 Acceleration Request Requested Date: April 23, 2025 Requested Time: 5:00 p.m. , Eastern Time

Re: Dermata Therapeutics, Inc.

Dear Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Dermata Therapeutics, Inc. (the "Company") hereby requests that the above-referenced Registration Statement (the "Registration Statement") be declared effective by the Securities and Exchange Commission (the "Commission") at the "Requested Date" and "Requested Time" set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.

Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.

Sincerely,
DERMATA THERAPEUTICS, INC.

Show Raw Text
CORRESP
 1
 filename1.htm

 April
21, 2025

 VIA
EDGAR

 United
States Securities and Exchange Commission

 Division
of Corporation Finance

 Mail
Stop 4720

 100
F Street, N.E.

 Washington,
D.C. 20549

 Re:
 Dermata
 Therapeutics, Inc.

 Registration
 Statement on Form S-3

 File
 No. 333-286547

 Acceleration Request

 Requested
 Date:
 April
 23, 2025

 Requested
 Time:
 5:00
 p.m. , Eastern Time

 Dear
Ladies and Gentlemen:

 Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Dermata Therapeutics, Inc. (the "Company") hereby requests that
the above-referenced Registration Statement (the "Registration Statement") be declared effective by the Securities and Exchange
Commission (the "Commission") at the "Requested Date" and "Requested Time" set forth above or at
such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance
of the Commission.

 Please
call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with
any questions.

 Sincerely,

 DERMATA THERAPEUTICS, INC.

 By:
 /s/
 Gerald T. Proehl

 Name:
 Gerald
 T. Proehl

 Title:
 Chief
 Executive Officer

 THIS
PAGE IS INTENTIONALLY LEFT BLANK
IT IS NOT A PART OF EDGAR SUBMISSION